BRAIDWELL LP
STAMFORD, CT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.41B2026 Q3
Positions88
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.30.7%
What Changed This Quarter?
Top Holdings
KOD
Kodiak Sciences
4.3%
CAI
Caris Life Sciences
3.5%
EWTX
Edgewise Therapeutics
3.5%
ATEC
Alphatec
3.1%
IRTC
iRhythm
3.0%
ATEC 0.75 03-15-30
Alphatec
2.9%
HNGE
Hinge Health
2.6%
SYRE
Spyre Therapeutics
2.6%
New / Increased
16 new · 20 increased
DMRANEW
Damora Therapeutics
1.5%
NVCTNEW
Nuvectis Pharma
1.4%
TEVANEW
Teva Pharmaceutical Industries
1.2%
CSTLNEW
Castle Biosciences
0.7%
SYKNEW
Stryker
0.6%
VERA
Vera Therapeutics
2.3%
+205.8%
ISRG
Intuitive Surgical
2.1%
+79.6%
XENE
Xenon Pharmaceuticals
2.6%
+51.0%
Reduced / Exited
38 reduced · 14 sold out
CAI
Caris Life Sciences
3.5%
-66.7%
KOD
Kodiak Sciences
4.3%
-39.3%
HNGE
Hinge Health
2.6%
-50.7%
GKOS
Glaukos
2.3%
-41.9%
TMO
Thermo Fisher Scientific
1.2%
-53.4%
Damora Therap…EXIT
Damora Therapeutics
1.6%
ACADEXIT
Acadia Pharmaceuticals
1.5%
CDNAEXIT
Caredx
1.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.